Navigation Links
SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery
Date:4/10/2008

Washington, D.C. (April 10, 2008) Carotid artery stenting is an effective option for high risk patients who are not eligible for surgery, according to a long-term study published in this weeks New England Journal of Medicine. Carotid artery disease, which involves clogging of the arteries in the neck that provide blood to the brain, is a significant risk factor for stroke, making these study results important for the estimated 200,000 Americans each year who would otherwise not be candidates for the treatment.

The SAPPHIRE trial showed patients undergoing carotid stenting were comparably protected from stroke, heart attack, death, and repeat revascularization procedures as patients who underwent the traditional surgical approach (endarterectomy). SAPPHIRE is the first and longest (three years) randomized study to compare the safety and efficacy of carotid stenting with embolic protection to surgery in high risk patients. High risk patients are considered to be at increased risk for surgery because of prior carotid artery surgery, radiation to the neck, chronic heart failure, lung disease or severe coronary artery disease, among other criteria.

The Society for Cardiovascular Angiography and Interventions (SCAI), the worlds leading society of interventional cardiologists, is encouraged by these positive data. Results are consistent with one-year SAPPHIRE data and echo conclusions from other non-randomized trials supporting the use of carotid stenting, particularly in patients with multiple illnesses.

This is more good news for patients who otherwise might not have treatment options, said Dr. Bonnie Weiner, president of the Society for Cardiovascular Angiography and Interventions. Carotid artery stenting is an effective, safe way to help patients avoid debilitating and potentially fatal strokes. We are hopeful that this news will help pave the way for expanded use of this procedure.

Carotid Artery Stenting

Carotid artery stenting is a non-surgical, percutaneous procedure in which a small plastic tube called a catheter is inserted through an artery in the leg and threaded to the blockage in the neck. A thin wire (guidewire), which has a collapsible umbrella-like filter device attached to its end, is advanced passed the blockage. The umbrella is opened and acts as a filter to the blood flowing to the brain, preventing particles from passing to the brain and causing stroke while opening up the blockage and inserting a tiny mesh tube called a stent. The blocked artery is then dilated by inflating a balloon, which pushes the plaque in the artery against its walls and makes way for the stent, which is inserted to prop open the artery. Once the stent is in place, the umbrella filter is removed.

SAPPHIRE

SAPPHIRE, a multi-center, prospective, randomized study, evaluated the safety and performance of the Cordis PRECISE® Nitinol Stent and AngioGuard® Emboli Capture Guidewire, compared with surgery, in 334 patients with carotid artery stenosis. The pre-specified major secondary endpoint at three years was a composite of death, stroke, or myocardial infarction within 30 days after the procedure or death or ipsilateral stroke (occurring on the same side) between 31 days and three years.

At three years, data were available for 260 patients, 85.6 percent of patients (143 of 167) in the stenting group and 70.1 percent of patients (117 of 167) in the surgery group. The pre-specified major secondary endpoint occurred in 41 of the 167 patients who underwent stenting (cumulative incidence, 24.6 percent) and in 45 of 167 patients who underwent endarterectomy (cumulative incidence, 26.9 percent). There was no statistical significance between these groups. Target-vessel revascularization (a procedure to re-open the blocked arteries) was infrequent in both groups.

Although this report is specific to the products mentioned above, it is consistent with results from registries using other similar devices. This supports the overall role of carotid stenting in this patient population.


'/>"/>

Contact: Kathy Boyd David
kbdavid@scai.org
712-422-1181
Society for Cardiovascular Angiography and Interventions
Source:Eurekalert

Related medicine news :

1. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
2. Stopping a cancer trial early: is it for the benefit of patients or industry?
3. Syndicoms Collaborative Web Platform Chosen to Facilitate Clinical Trials for Lumbar Disc Device from Aesculap Implant Systems
4. Surgeons announce advance in atrial fibrillation surgery
5. Clinical trial volunteers mostly indifferent -- but not blind to -- researchers financial conflicts
6. Clinical trial will test new HIV/AIDS vaccine
7. Knowing doctors financial interests doesnt deter clinical trial participants
8. Report Claims Clinical Trials Miss Many Populations
9. Renal artery stenting falls short in large randomized trial
10. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
11. Some Cancer Trials Overstate Findings, Analysis Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016   Click here for supplemental ... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ... agreement to acquire Valley Campus Pharmacy, Inc., doing ... leading specialty pharmacy that provides individualized patient care, ... . In 2015, TNH generated approximately $400 million ...
(Date:4/28/2016)... , April 28, 2016  Marking its one ... breast and ovarian cancer risk test, Color ... 30 genes that highly impact the most common ... today, the Color Test analyzes hereditary cancer risks ... and uterine cancers. The Color Test is physician ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology: